A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy

Trial Profile

A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 21 Jun 2018 Planned End Date changed from 19 Sep 2019 to 19 Sep 2018.
    • 21 Jun 2018 Planned primary completion date changed from 27 Feb 2018 to 19 Sep 2018.
    • 11 Feb 2018 Planned End Date changed from 10 Sep 2019 to 19 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top